Difference between revisions of "Forodesine (Fodosine)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Purine nucleoside phosphorylase (PNP) inhibitor ==Preliminary data== # Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, ...") |
Warner-admin (talk | contribs) m (Text replacement - "analogue" to "analog") |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/forodesine-hydrochloride NCI Drug Dictionary]: The hydrochloride salt of the synthetic high-affinity transition-state analog forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes. | |
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Peripheral T-cell lymphoma]] | |
| − | [[ | + | ==History of changes in PMDA indication== |
| + | *2017-03-30: Initial approval for the treatment of relapsed or refractory [[peripheral T-cell lymphoma]]. | ||
| + | ==Also known as== | ||
| + | *'''Code name:''' BCX-1777 | ||
| + | *'''Generic name:''' immucillin H | ||
| + | *'''Brand name:''' Fodosine, Mundesine | ||
| − | [[Category:T-cell lymphoma medications]] | + | [[Category:Drugs]] |
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Purine nucleoside phosphorylase (PNP) inhibitors]] | ||
| + | |||
| + | [[Category:Peripheral T-cell lymphoma medications]] | ||
| + | |||
| + | [[Category:PMDA approved in 2017]] | ||
Latest revision as of 13:50, 23 September 2023
Mechanism of action
From the NCI Drug Dictionary: The hydrochloride salt of the synthetic high-affinity transition-state analog forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes.
Diseases for which it is used
History of changes in PMDA indication
- 2017-03-30: Initial approval for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Also known as
- Code name: BCX-1777
- Generic name: immucillin H
- Brand name: Fodosine, Mundesine